The phase II INSIGHT 2 study (NCT03940703) is currently investigating tepotinib plus osimertinib in patients with EGFR-mutant NSCLC with acquired resistance to prior EGFR TKIs due to MET amplification. The gene discussed is MET; the disease is non-small cell lung carcinoma.